9/17/2020 | DD | Endologix third amended pre-packaged plan of reorganization confirmed
|
8/21/2020 | DD | Endologix granted approval to implement key employee incentive plan
|
8/11/2020 | DD | Endologix granted approval to implement key employee retention plan
|
8/3/2020 | DD | Endologix creditors object to statement, seek deferral of plan hearing
|
7/31/2020 | DD | Endologix: U.S. Trustee raises objections to plan release provisions
|
7/20/2020 | DD | Endologix: Five-member official unsecured creditors committee formed
|
7/10/2020 | BKCVDDEMHY | Prospect News reports nine new defaults for week of July 2 to July 8
|
7/8/2020 | DD | Endologix gets interim access to $10 million in new-money financing
|
7/6/2020 | BKCVDDHY | Endologix files pre-packaged bankruptcy; Deerfield Partners to swap debt for equity
|
2/24/2020 | CVLMPV | Endologix to swap some 2020 convertibles, amend debt facilities
|
1/16/2020 | BKBWCVHY | Endologix reports completion of a ‘major debt refinancing’ in 2019
|
4/1/2019 | HYIG | Market Commentary: Valley Republic secures $20 million; Mustang Bio gets debt financing
|
4/1/2019 | PV | Market Commentary: Valley Republic secures $20 million; Mustang Bio gets debt financing
|
4/1/2019 | CVLM | Endologix holders exchange $73.36 million 3.25% convertible notes
|
4/1/2019 | BKPV | Endologix extends Deerfield credit agreement to 2023, edits covenants
|
10/24/2018 | CVLM | Endologix to redeem 2.25% convertible notes via stock sale proceeds
|
1/8/2018 | BK | Endologix terminates Deerfield credit facility, to get replacement loan
|
4/4/2017 | BK | Endologix obtains $170 million credit agreement from Deerfield
|
4/4/2017 | CVLM | Endologix to repurchase $53.1 million 2.25% convertibles due 2018
|
11/16/2016 | CV | Market Commentary: Weatherford, AMD gain; Endologix drops sharply; Medicines up; PDL BioPharma deal on tap
|
2/3/2016 | PV | TriVascular loans repaid, terminated after acquisition by Endologix
|
12/31/2015 | CV | Market Commentary: Outlook 2016: Convertibles primary market seen in line to higher after disappointing 2015
|
10/29/2015 | CV | Endologix greenshoe exercise increases convertibles to $125 million
|
10/28/2015 | PP | Market Commentary: Downsized Endologix trades up on debut; Kinder Morgan trades better; Integrated Device Technology on tap
|
10/28/2015 | CV | Market Commentary: Downsized Endologix trades up on debut; Kinder Morgan trades better; Integrated Device Technology on tap
|
10/28/2015 | CV | Market Commentary: Morning Commentary: Downsized Endologix trades up on debut; Kinder Morgan better; Twitter shares sink
|
10/28/2015 | CV | New Issue: Endologix prices downsized $110 million five-year convertible notes to yield 3.25%, up 27.5%
|
10/27/2015 | PP | Market Commentary: Kinder Morgan mandatory trades lower on debut, Endologix shares plunge ahead of pricing
|
10/27/2015 | CV | Market Commentary: Kinder Morgan mandatory trades lower on debut, Endologix shares plunge ahead of pricing
|
10/27/2015 | CV | Market Commentary: Morning Commentary: New Kinder Morgan mandatory trades lower, Endologix shares plunge
|
10/26/2015 | PP | Market Commentary: Kinder Morgan plans $1.6 billion mandatory; Endologix on tap for $150 million; Ctrip jumps in active trade
|
10/26/2015 | CV | Market Commentary: Kinder Morgan plans $1.6 billion mandatory; Endologix on tap for $150 million; Ctrip jumps in active trade
|
10/26/2015 | CV | Endologix to price $150 million three-year convertibles to yield 2.75%-3.25%, up 27.5%-32.5%
|
3/3/2014 | CV | Market Commentary: Tesla lags from issue; Yandex slumps on Russia-Ukraine conflict; Akorn down after earnings
|
12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
12/9/2013 | CV | Endologix greenshoe lifts 2.25% convertibles to $86.25 million
|
12/6/2013 | CV | Market Commentary: Proofpoint adds on hedge as shares fade; HCI Group adds on debut; secondary market quiet
|
12/6/2013 | BK | Endologix amends credit agreement to permit convertibles issue
|
12/6/2013 | CV | Market Commentary: Midday Commentary: New Proofpoint, HCI add on hedge; GT Advanced, Endologix, SouFun shares lower
|
12/5/2013 | CV | New Issue: Endologix prices $75 million five-year convertible notes to yield 2.25%, up 32.5%
|
12/5/2013 | CV | Market Commentary: GT Advanced, Endologix gain on hedge; SouFun, American Realty mostly in line; RAIT drops
|
12/4/2013 | CV | Market Commentary: Midday Commentary: New RPM International adds early on debut; RAIT Financial launches deal
|
12/4/2013 | CV | Market Commentary: RPM gains outright on debut; planned GT Advanced deal talk tightened; existing GT in line
|
12/3/2013 | CV | Endologix plans $75 million five-year convertibles to yield 2.25%-2.75%, up 27.5%-32.5%
|
12/3/2013 | CV | Market Commentary: New Orexigen trends toward par; planned RPM deal in focus; GT Advanced, Endologix on tap
|
5/31/2012 | PP | Endologix prices $36.18 million public stock sale at $13.40 per share
|
5/30/2012 | CVHYPF | Endologix files automatic shelf covering debt, stock and preferreds
|
10/27/2010 | PP | Endologix to pocket $15 million through private placement of shares
|
11/25/2009 | SS | Endologix investor Elliott Associates drops ownership stake to 7.1%
|
5/8/2009 | CV | Endologix files $50 million shelf registration covering stock, debt
|
11/13/2008 | SS | Endologix turns down Elliott Associates' $2.25-per-share offer
|
10/14/2008 | SS | Elliott Associates wants to buy Endologix for $2.25 per share
|
4/7/2008 | SS | Elliott buys shares of Endologix
|
6/2/2006 | PP | Market Commentary: Jed Oil wraps $34.33 million convertible offering; Jones Soda secures $30 million from stock sale
|
6/1/2006 | BT | Market Commentary: Targeted Genetics' stock jumps 18% on promising data; Endologix raises $20.13 million from stock sale
|
6/1/2006 | PP | Market Commentary: Endologix secures $20.13 million from direct stock deal; Numerex raises $10 million from notes
|
6/1/2006 | BTPP | New Issue: Endologix secures $20.13 million from direct placement of stock
|
5/24/2006 | BT | Endologix receives FDA approval for Visiflex delivery system
|
4/27/2006 | BT | Endologix files $50 million stock shelf
|
4/25/2006 | BT | Endologix receives FDA approval for smaller-size stent grafts
|
3/16/2006 | BT | Endologix's 10-K report includes 'going concern' warning
|
2/16/2006 | BT | Follow-up data support safety, effectiveness of Endologix's Powerlink System
|
7/6/2005 | PP | Market Commentary: SmarTire raises $190 million in private placements; oil surges over $61 a barrel, fueling energy offerings
|
7/6/2005 | BTPP | New Issue: Endologix secures $16.6 million from private placement of shares
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|